Glucagon-like peptide 1 receptor agonists and cancer risk: advancing precision medicine through mechanistic understanding and clinical evidence

Glucagon-like peptide 1 receptor agonists and cancer risk: advancing precision medicine through mechanistic understanding and clinical evidence

Abstract Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have emerged as a primary first-line treatment for type 2 diabetes. This has raised concerns about their impact on cancer risk, spurring extensive research. This review systematically examines the varied effects of GLP-1RAs on the risk of...

Full description

Saved in:
Bibliographic Details
Main Authors: Anqi Lin, Yanxi Ding, Zhengrui Li, Aimin Jiang, Zaoqu Liu, Hank Z. H. Wong, Quan Cheng, Jian Zhang, Peng Luo
Format: Article
Language:English
Published: BMC 2025-03-01
Series:Biomarker Research
Subjects:
Glucagon-like peptide-1 receptor agonists
GLP-1-RAs
Precision medicine
Cancer risk
Online Access:https://doi.org/10.1186/s40364-025-00765-3
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s40364-025-00765-3

Similar Items